Cardium Therapeutics

Cardium Therapeutics, Inc. is a medical technology company primarily focused on the development, manufacture and sale of innovative products for cardiovascular and related indications, which are leading healthcare priorities in the U.S. and the world. We are in the process of building a business that balances products for “today” that are either currently marketed or have advanced to near-term sales or partnering opportunities, as well as breakthrough products for “tomorrow”. We are leading a revolution into the new frontiers of cardiovascular and regenerative medicine and are assembling a portfolio of forward-focused therapeutic biologics and medical devices designed to transform the practice of medicine. They each have well-defined commercial pathways and represent substantial economic opportunities. While varied in approach, our portfolio is uniformly directed to the prevention and treatment of ischemic injuries. Our biologics and medical devices are designed to leverage the human body’s natural capacity to heal, protect and repair. Unlike small molecule, chronic-use drugs that typically provide only symptomatic relief, the planned products in our portfolio are being designed for one-time application to heal and repair the underlying medical condition or to prevent further injury in acute or surgical settings.

Contact Details: 3611 Valley Centre, Suite 525 San Diego CA 92130 United States of America Tel: (858) 436-1000 Fax: (858) 436-1001 Email: investorrelations@cardiumthx.com WWW: www.cardiumthx.com/

Loading...

Press Releases on Cardium Therapeutics:
Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments	10th November, 2009	Cardium Therapeutics	-- Listing compliance with the NYSE Amex. Sale of InnerCool Therapies to Royal Philips Electronics During third quarter 2009, Cardium announced the completion of the sale of its InnerCool
Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds	2nd November, 2009	Cardium Therapeutics	SAN DIEGO, Nov. 2 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced plans to submit a 510(k) premarket notification with the U.S. Food and Drug Administration (FDA)
Cardium Completes $6.0 Million Registered Direct Offering	20th October, 2009	Cardium Therapeutics	SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced that it has completed its previously announced $6.0 million registered direct offering of common
Cardium Announces Planned Release of Data from Matrix Excellarate Phase 2b Clinical Study and Acceptance of Phase 1 / 2 Study for Publication in Wound Repair and Regeneration	1st October, 2009	Cardium	SAN DIEGO, Oct. 1 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) announced plans to report on preliminary safety and efficacy data from its Matrix Phase 2b Excellarate clinical study.
Cardium Receives Preliminary Notification of Inclusion in the Russell 3000(R) Index and Russell Global(R) Index	17th June, 2009	Cardium Therapeutics	SAN DIEGO, June 17 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced it is scheduled to join the broad-market Russell 3000 Index when Russell Investments reconstitutes

BioNews Results for Cardium Therapeutics:
Biotech Stock Mailbag: Cardium Therapeutics	TheStreet.com:  Nov 13 2009 10:11AM Matching: cardium therapeutics
PicksThatMove.com Announces Investment Opinion on Oro Silver Resources, Alcoa Inc., Cardium Therapeutics Inc., Altima Resources Ltd. and Citadel Broadcasting Corporation	SmartBrief:  Nov 11 2009 4:57AM Matching: cardium therapeutics
Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments	Montana's News Station:  Nov 10 2009 11:11PM Matching: cardium therapeutics
Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments	KOTA Territory News:  Nov 10 2009 8:52PM Matching: cardium therapeutics
Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments	Genetic Engineering News:  Nov 10 2009 8:44PM Matching: cardium therapeutics
Promote your company here: BioNewsCast - Press Release Distribution	→View more Cardium Therapeutics news.

Cardium Therapeutics Clinical Trials:
Efficacy and Safety of Intracoronary Ad5FGF-4 in Patients With Stable Angina (AGENT-3)

Cardium Therapeutics (CDTP.OB) Financial information Links from Barchart
CDTP.OB Quote from from Barchart.com
CDTP.OB Chart from from Barchart.com
CDTP.OB Profile from from Barchart.com
CDTP.OB Opinion from from Barchart.com
→View more Cardium Therapeutics finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 354 times since April 2007, the link to the organisation's website has been followed 73 times

Search for more companies in San Diego

Search for more companies in CA

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Cardium Therapeutics